Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aslan Pharmaceuticals Ltd ADR (NQ: ASLN )

0.6000 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aslan Pharmaceuticals Ltd ADR

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why iMedia Brands Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Prestige Wealth Inc. (NASDAQ: PWM) shares jumped 65.6% to $8.28. Prestige Wealth reported pricing of $5 million initial public offering of 1 million shares of common stock at a price of $5 per... 
Via Benzinga
4 Analysts Have This to Say About ASLAN Pharma
Via Benzinga
Dow Drops 75 Points; US Economy Adds 209,000 Jobs In June
U.S. stocks traded mostly lower this morning, with the Dow Jones dropping around 75 points on Friday. Following the market opening Friday, the Dow traded down 0.22% to 33,847.30 while the NASDAQ fell... 
Via Benzinga
Nasdaq Drops Over 100 Points; Genius Sports Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping over 100 points on Thursday. The Dow traded down 1.09% to 33,913.56 while the NASDAQ fell 0.96% to 13,659.77. The... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Moves Lower; ISM Services PMI Surges In June
U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 450 points on Thursday. The Dow traded down 1.38% to 33,814.23 while the NASDAQ fell 1.37% to 13,602.19. The S&P 500,... 
Via Benzinga
Why Caribou Biosciences Shares Are Trading Higher By Around 58%? Here Are Other Stocks Moving In Thursday's Session
Gainers Caribou Biosciences, Inc. (NASDAQ: CRBU) shares jumped 58.1% to $6.45 after the company announced a $25 million equity investment from Pfizer. 
Via Benzinga
Dow Tumbles Over 300 Points; US Jobless Claims Increase More Than Projected
U.S. stocks traded lower this morning, with the Dow Jones dropping over 300 points on Thursday. Following the market opening Thursday, the Dow traded down 0.96% to 33,958.13 while the NASDAQ fell 1.06%... 
Via Benzinga
What's Going On With ASLAN Pharmaceuticals Stock Today?
ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) released topline data from its TREK-AD Phase 2b dose-ranging study of eblasakimab in adult patients with moderate-to-severe  
Via Benzinga
Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic Dermatitis
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab’s Unique Mechanism of Action in the Treatment of Atopic Dermatitis
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Inks Licensing Deal With Zenyaku Kogyo To Commercialize Eblasakimab In Japan
ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) inked a strategic licensing deal with Zenyaku Kogyo to develop and  
Via Benzinga
ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023
Via Benzinga
ASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia Areata
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Presents New Data on Eblasakimab and Farudodstat in Two Late-Breaking Presentations at the 1st International Societies for Investigative Dermatology Meeting
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Announces Four Abstracts on Eblasakimab and Farudodstat, Including Two Late-Breakers, to be Presented at the 1st International Societies for Investigative Dermatology Meeting
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals to Participate in Fireside Chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
10 Short Squeeze Candidates: PaxMedica, Blue Apron, MicroStrategy And More
Potential short squeeze plays gained steam in 2021 and continued through 2022 with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits... 
Via Benzinga
ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals to Host Virtual Research and Development Day on Novel DHODH Inhibitor Farudodstat for Alopecia Areata
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.